Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation. Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yuqi Yang, Ning Ji, Qiu-Xu Teng, Chao-Yun Cai, Jing-Quan Wang, Zhuo-Xun Wu, Zi-Ning Lei, Sabrina Lusvarghi, Suresh V. Ambudkar, Zhe-Sheng Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2020-05-01
Edice:	Frontiers in Oncology
Témata:	sitravatinib tyrosine kinase inhibitor multidrug resistance ATP-binding cassette (ABC) transporters ATP-binding cassette super-family G member 2 (ABCG2)
On-line přístup:	https://www.frontiersin.org/article/10.3389/fonc.2020.00700/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!